Effect of adenosine deaminase on cardiac interstitial adenosine

1992 ◽  
Vol 263 (4) ◽  
pp. H1322-H1326 ◽  
Author(s):  
Q. Zhu ◽  
G. P. Matherne ◽  
R. R. Curnish ◽  
C. G. Tribble ◽  
R. M. Berne

Adenosine deaminase was infused into isolated perfused guinea pig hearts to determine its effect on myocardial adenosine levels. The enzyme was administered during constant coronary flow perfusion at 6.11 +/- 0.36 ml.min-1.g-1. Venous adenosine was measured in samples of pulmonary artery effluent; epicardial and endocardial adenosine were measured with the porous nylon disk technique. Infusion of adenosine deaminase at 2.4 and 4.8 U/ml produced adenosine deaminase activity of 0.92 +/- 0.09 and 2.33 +/- 0.15 U/ml, respectively, in epicardial fluid and 1.93 +/- 0.28 and 4.84 +/- 0.47 U/ml, respectively, in endocardial fluid. Aortic pressure was unchanged by infusion of adenosine deaminase at both infusion rates. Adenosine deaminase (data from both infusion rates pooled) reduced epicardial adenosine from 0.327 +/- 0.028 to 0.139 +/- 0.022 microM, endocardial adenosine from 4.61 +/- 0.42 to 1.64 +/- 0.20 microM, and venous adenosine from 0.017 +/- 0.02 to 0.003 +/- 0.001 microM. The data indicate that infused adenosine deaminase reaches the epicardial and endocardial interstitial fluid (ISF) compartments. The absence of any effect on coronary pressure suggests that adenosine may not be involved in resting basal coronary tone. The presence of significant residual adenosine despite adenosine deaminase infusion indicates that adenosine production in the unstressed isolated guinea pig heart exceeds the degradative capacity of infused adenosine deaminase. Previous studies in which it was assumed that almost all of the endogenous adenosine is inactivated by the infusion of adenosine deaminase should be reevaluated in light of these observations.

Sensors ◽  
2018 ◽  
Vol 18 (8) ◽  
pp. 2441 ◽  
Author(s):  
Xinxing Tang ◽  
Kefeng Wu ◽  
Han Zhao ◽  
Mingjian Chen ◽  
Changbei Ma

Adenosine deaminase (ADA), able to catalyze the irreversible deamination of adenosine into inosine, can be found in almost all tissues and plays an important role in several diseases. In this work, we developed a label-free fluorescence method for the detection of adenosine deaminase activity and inhibition. In the presence of ADA, ATP has been shown to be hydrolyzed. The ATP aptamer was shown to form a G-quadruplex/thioflavin T (ThT) complex with ThT and exhibited an obvious fluorescence signal. However, the ATP aptamer could bind with ATP and exhibited a low fluorescence signal because of the absence of ADA. This assay showed high sensitivity to ADA with a detection limit of 1 U/L based on an SNR of 3 and got a good linear relationship within the range of 1–100 U/L with R2 = 0.9909. The LOD is lower than ADA cutoff value (4 U/L) in the clinical requirement and more sensitive than most of the reported methods. This technique exhibited high selectivity for ADA against hoGG I, UDG, RNase H and λexo. Moreover, this strategy was successfully applied for assaying the inhibition of ADA using erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and, as such, demonstrated great potential for the future use in the diagnosis of ADA-relevant diseases, particularly in advanced drug development.


2005 ◽  
Vol 391 (1) ◽  
pp. 51-57 ◽  
Author(s):  
Andrey V. Zavialov ◽  
Åke Engström

Two distinct isoenzymes of ADA (adenosine deaminase), ADA1 and ADA2, have been found in humans. Inherited mutations in ADA1 result in SCID (severe combined immunodeficiency). This observation has led to extensive studies of the structure and function of this enzyme that have revealed an important role for it in lymphocyte activation. In contrast, the physiological role of ADA2 is unknown. ADA2 is found in negligible quantities in serum and may be produced by monocytes/macrophages. ADA2 activity in the serum is increased in various diseases in which monocyte/macrophage cells are activated. In the present study, we report that ADA2 is a heparin-binding protein. This allowed us to obtain a highly purified enzyme and to study its biochemistry. ADA2 was identified as a member of a new class of ADGFs (ADA-related growth factors), which is present in almost all organisms from flies to humans. Our results suggest that ADA2 may be active in sites of inflammation during hypoxia and in areas of tumour growth where the adenosine concentration is significantly elevated and the extracellular pH is acidic. Our finding that ADA2 co-purified and concentrated together with IgG in commercially available preparations offers an intriguing explanation for the observation that treatment with such preparations leads to non-specific immune-system stimulation.


2003 ◽  
Vol 285 (3) ◽  
pp. H1040-H1047 ◽  
Author(s):  
Mark W. Gorman ◽  
Kayoko Ogimoto ◽  
Margaret V. Savage ◽  
Kenneth A. Jacobson ◽  
Eric O. Feigl

The role of P1 receptors and P2Y1 receptors in coronary vasodilator responses to adenine nucleotides was examined in the isolated guinea pig heart. Bolus arterial injections of nucleotides were made in hearts perfused at constant pressure. Peak increase in flow was measured before and after addition of purinoceptor antagonists. Both the P1 receptor antagonist 8-( p-sulfophenyl)theophylline and adenosine deaminase inhibited adenosine vasodilation. AMP-induced vasodilation was inhibited by P1 receptor blockade but not by adenosine deaminase or by the selective P2Y1 antagonist N6-methyl-2′-deoxyadenosine 3′,5′-bisphosphate (MRS 2179). ADP-induced vasodilation was moderately inhibited by P1 receptor blockade and greatly inhibited by combined P1 and P2Y1 blockade. ATP-induced vasodilation was antagonized by P1 blockade but not by adenosine deaminase. Addition of P2Y1 blockade to P1 blockade shifted the ATP dose-response curve further rightward. It is concluded that in this preparation ATP-induced vasodilation results primarily from AMP stimulation of P1 receptors, with a smaller component from ATP or ADP acting on P2Y1 receptors. ADP-induced vasodilation is largely due to P2Y1 receptors, with a smaller contribution by AMP or adenosine acting via P1 receptors. AMP responses are mediated solely by P1 receptors. Adenosine contributes very little to vasodilation resulting from bolus intracoronary injections of ATP, ADP, or AMP.


1990 ◽  
Vol 259 (5) ◽  
pp. H1471-H1476 ◽  
Author(s):  
C. S. Tietjan ◽  
C. G. Tribble ◽  
J. M. Gidday ◽  
C. L. Phillips ◽  
L. Belardinelli ◽  
...  

Epicardial porous disks were used to estimate left ventricular interstitial fluid adenosine in the isolated guinea pig heart perfused at constant flow. To validate this technique, adenosine was infused with 0.5 microM dipyridamole and 5 microM erythro-4-(2-hydroxy-3-nonyl)adenine hydrochloride (EHNA) to inhibit adenosine uptake and deamination, respectively. Under these conditions, with 6 or 12 microM adenosine in the arterial infusate, the venous and steady-state left ventricular disk adenosine values equaled those of the perfusion fluid, reflecting the expected equilibration between vascular and left ventricular interstitial fluid (disk) compartments. The concentration of endogenous adenosine in the interstitial fluid as estimated by the epicardial disks under control conditions was 0.28 +/- 0.03 microM with a concomitant coronary sinus concentration of 0.004 +/- 0.001 microM. We conclude that a marked adenosine gradient exists between the interstitial fluid and the vascular space and that disk adenosine measurements provide a useful index of left ventricular interstitial fluid adenosine.


1993 ◽  
Vol 264 (3) ◽  
pp. H821-H829 ◽  
Author(s):  
I. P. Brown ◽  
C. I. Thompson ◽  
F. L. Belloni

To test the hypothesis that nitric oxide (NO) mediates hypoxic coronary dilatation in situ, isolated guinea pig hearts were perfused at constant pressure (Langendorff technique) with physiological salt solution. Switching from a control perfusate (95% O2-5% CO2) to one equilibrated with a lower O2 tension (20% O2) induced a large, but submaximal and reproducible, coronary dilatation. The NO synthase inhibitor NG-nitro-L-arginine (L-NNA) diminished baseline flow (3.67 +/- 0.24 vs. control 5.11 +/- 0.42 ml.min-1 x g-1; P < 0.05) and selectively blocked the coronary flow response to acetylcholine without reducing the response to papaverine. L-NNA reduced the absolute increase in coronary flow during hypoxia by 27 +/- 2% (delta flow = 5.83 +/- 0.49 vs. control delta flow = 8.04 +/- 0.74 ml.min-1 x g-1; P < 0.05). Hypoxic coronary dilatation was unaffected by infusion of the thromboxane mimetic U-46619, which decreased baseline coronary flow to the same extent as L-NNA. Prior addition of indomethacin did not alter the attenuating effect of L-NNA. Hypoxic coronary dilatation during constant flow perfusion at 14.7 +/- 0.28 ml/min was reduced by 65 +/- 5% after L-NNA. Therefore, the NO component of the response was not a consequence of the reduced baseline flow observed in the presence of L-NNA, did not depend on prostaglandin synthesis, and was not secondary to increased flow or intravascular shear stress. We conclude that hypoxic coronary vasodilatation in isolated guinea pig hearts is partially mediated by NO.


Author(s):  
W. Allen Shannon ◽  
Hannah L. Wasserkrug ◽  
andArnold M. Seligman

The synthesis of a new substrate, p-N,N-dimethylamino-β-phenethylamine (DAPA)3 (Fig. 1) (1,2), and the testing of it as a possible substrate for tissue amine oxidase activity have resulted in the ultracytochemical localization of enzyme oxidase activity referred to as DAPA oxidase (DAPAO). DAPA was designed with the goal of providing an amine that would yield on oxidation a stronger reducing aldehyde than does tryptamine in the histochemical demonstration of monoamine oxidase (MAO) with tetrazolium salts.Ultracytochemical preparations of guinea pig heart, liver and kidney and rat heart and liver were studied. Guinea pig kidney, known to exhibit high levels of MAO, appeared the most reactive of the tissues studied. DAPAO reaction product appears primarily in mitochondrial outer compartments and cristae (Figs. 2-4). Reaction product is also localized in endoplasmic reticulum, cytoplasmic vacuoles and nuclear envelopes (Figs. 2 and 3) and in the sarcoplasmic reticulum of heart.


1988 ◽  
Vol 47 (5) ◽  
pp. 394-397 ◽  
Author(s):  
I Ocana ◽  
E Ribera ◽  
J M Martinez-Vazquez ◽  
I Ruiz ◽  
E Bejarano ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document